MetaCap

CeriBell (CBLL) vs CapsoVision (CV)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CeriBell (CBLL) has outperformed CapsoVision (CV) over the past year, gaining 79.5% versus a gain of 16.8%. CeriBell is the larger company by market cap ($1.06 billion vs $327.6 million), about 3.2 times the size. CeriBell converts more of its revenue into profit, with a net margin of -60.0% versus -186.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CBLL+79.49%CV+16.83%
+185%+82%-21%
Nov 21, 20251 yearNov 20, 2026
CBLL+44.69%CV+38.86%
+213%+80%-52%
Jun 30, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CBLL versus CV key metrics
MetricCBLLCV
Share price$27.39$6.11
Market cap$1.06B$327.56M
1-day change+6.37%-3.17%
YTD return+24.90%-42.84%
1-year return+79.49%+16.83%
EPS (TTM)$-1.95$-0.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$89.06M$13.55M
Revenue growth (YoY)+36.09%+15.29%
Net income (latest FY)$-53.41M$-25.32M
Gross margin87.89%52.92%
Operating margin-65.57%-188.25%
Net margin-59.97%-186.77%
52-week high$28.89$15.37
52-week low$14.87$4.50
Distance from 52-week high-5.19%-60.25%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+15.26%+55.48%
Average volume452.64K173.59K
Shares outstanding38.84M53.61M
Employees32799
SectorHealth CareHealth Care
IndustryBiotechnology: Electromedical & Electrotherapeutic ApparatusBiotechnology: Electromedical & Electrotherapeutic Apparatus

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CeriBell is about 3.2 times larger than CapsoVision by market value ($1.06B vs $327.56M).
  • CBLL has outperformed CV by 62.7 percentage points over the past year.
  • CeriBell is more profitable, keeping -60.0 cents of every revenue dollar as net income versus -186.8 cents for CapsoVision.
  • CeriBell grew revenue faster in its latest fiscal year (+36.09% vs +15.29%).

About CeriBell

CBLL stock →

CeriBell, Inc. operates as a medical technology company in the United States.

Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 327 employees

About CapsoVision

CV stock →

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).

Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 99 employees

CBLL vs CV FAQ

Which is bigger, CeriBell or CapsoVision?

CeriBell (CBLL) is larger, with a market capitalization of $1.06B compared with $327.56M for CapsoVision (CV).

Which stock has performed better over the past year, CBLL or CV?

CBLL returned +79.49% over the past 12 months, compared with +16.83% for CV (price return, excluding dividends). Past performance does not predict future results.

Are CeriBell and CapsoVision in the same industry?

Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.

More comparisons